|
1
|
Sawabata N, Miyaoka E, Asamura H,
Nakanishi Y, Eguchi K, Mori M, Nomori H, Fujii Y, Okumura M, Yokoi
K, et al: Japanese lung cancer registry study of 11,663 surgical
cases in 2004: Demographic and prognosis changes over decade. J
Thorac Oncol. 6:1229–1235. 2011.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Chemotherapy in non-small cell lung
cancer. A meta-analysis using updated data on individual patients
from 52 randomised clinical trials. Non-small Cell Lung Cancer
Collaborative Group. BMJ. 311:899–909. 1995.PubMed/NCBI
|
|
3
|
Arriagada R, Bergman B, Dunant A, Le
Chevalier T, Pignon JP and Vansteenkiste J: International Adjuvant
Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant
chemotherapy in patients with completely resected non-small-cell
lung cancer. N Engl J Med. 350:351–360. 2004.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Winton T, Livingston R, Johnson D, Rigas
J, Johnston M, Butts C, Cormier Y, Goss G, Inculet R, Vallieres E,
et al: Vinorelbine plus cisplatin vs. observation in resected
non-small-cell lung cancer. N Engl J Med. 352:2589–2597.
2005.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Douillard JY, Rosell R, De Lena M,
Carpagnano F, Ramlau R, Gonzáles-Larriba JL, Grodzki T, Pereira JR,
Le Groumellec A, Lorusso V, et al: Adjuvant vinorelbine plus
cisplatin versus observation in patients with completely resected
stage IB-IIIA non-small-cell lung cancer (Adjuvant navelbine
international trialist association [ANITA]): A randomised
controlled trial. Lancet Oncol. 7:719–727. 2006.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Butts CA, Ding K, Seymour L,
Twumasi-Ankrah P, Graham B, Gandara D, Johnson DH, Kesler KA, Green
M, Vincent M, et al: Randomized phase III trial of vinorelbine plus
cisplatin compared with observation in completely resected stage IB
and II non-small-cell lung cancer: Updated survival analysis of
JBR-10. J Clin Oncol. 28:29–34. 2010.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Bennouna J, Senellart H, Hiret S,
Vaissiere N and Douillard JY: Impact of histology on survival of
resected non-small cell lung cancer (NSCLC) receiving adjuvant
chemotherapy: Subgroup analysis of the adjuvant vinorelbine (NVB)
cisplatin (CDDP) versus observation in the ANITA trial. Lung
Cancer. 74:30–34. 2011.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Pignon JP, Tribodet H, Scagliotti GV,
Douillard JY, Shepherd FA, Stephens RJ, Dunant A, Torri V, Rosell
R, Seymour L, et al: Lung adjuvant cisplatin evaluation: A pooled
analysis by the LACE Collaborative Group. J Clin Oncol.
26:3552–3559. 2008.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Douillard JY, Tribodet H, Aubert D,
Shepherd FA, Rosell R, Ding K, Veillard AS, Seymour L, Le Chevalier
T, Spiro S, et al: Adjuvant cisplatin and vinorelbine for
completely resected non-small cell lung cancer: Subgroup analysis
of the lung adjuvant cisplatin evaluation. J Thorac Oncol.
5:220–228. 2010.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Ettinger DS, Wood DE, Aisner DL, Akerley
W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D'Amico
TA, et al: NCCN guidelines insights: Non-small cell lung cancer,
version 2.2021. J Natl Compr Canc Netw. 19:254–266. 2021.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Yamaguchi M, Takeo S, Suemitsu R and
Matsuzawa H: Feasibility study for biweekly administration of
cisplatin plus gemcitabine as adjuvant-chemotherapy for completely
resected non-small cell lung cancer. Cancer Chemother Pharmacol.
66:107–112. 2010.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Ohe Y, Ohashi Y, Kubota K, Tamura T,
Nakagawa K, Negoro S, Nishiwaki Y, Saijo N, Ariyoshi Y and Fukuoka
M: Randomized phase III study of cisplatin plus irinotecan versus
carboplatin plus paclitaxel, cisplatin plus gemcitabine, and
cisplatin plus vinorelbine for advanced non-small-cell lung cancer:
Four-Arm cooperative study in Japan. Ann Oncol. 18:317–323.
2007.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Kenmotsu H, Yamamoto N, Yamanaka T,
Yoshiya K, Takahashi T, Ueno T, Goto K, Daga H, Ikeda N, Sugio K,
et al: Randomized phase III study of pemetrexed plus cisplatin
versus vinorelbine plus cisplatin for completely resected stage II
to IIIA nonsquamous non-small-cell lung cancer. J Clin Oncol.
38:2187–2196. 2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Kenmotsu H, Ohde Y, Wakuda K, Nakashima K,
Omori S, Ono A, Naito T, Murakami H, Kojima H, Takahashi S, et al:
Survival data for postoperative adjuvant chemotherapy comprising
cisplatin plus vinorelbine after complete resection of non-small
cell lung cancer. Cancer Chemother Pharmacol. 80:609–614.
2017.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Furukawa N, Kawaguchi R and Kobayashi H:
Use of high-dose cisplatin with aprepitant in an outpatient
setting. Eur J Cancer Care (Engl). 21:436–441. 2012.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Sonobe M, Okubo K, Teramukai S, Yanagihara
K, Sato M, Sato T, Chen F, Sato K, Fujinaga T, Shoji T, et al:
Phase II study of adjuvant vinorelbine and cisplatin in Japanese
patients with completely resected stage II and III non-small cell
lung cancer. Cancer Chemother Pharmacol. 74:1199–1206.
2014.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Ng TL, Hutton B and Clemons M:
Chemotherapy-induced nausea and vomiting: Time for more emphasis on
nausea? Oncologist. 20:576–583. 2015.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Takiguchi Y, Moriya T, Asaka-Amano Y,
Kawashima T, Kurosu K, Tada Y, Nagao K and Kuriyama T: Phase II
study of weekly irinotecan and cisplatin for refractory or
recurrent non-small cell lung cancer. Lung Cancer. 58:253–259.
2007.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Ozawa Y, Inui N, Naitoh T, Yasuda K,
Nagayama M, Shirai T, Suganuma H, Fujii M, Nakamura H, Suda T and
Chida K: Phase II study of combination chemotherapy with S-1 and
weekly cisplatin in patients with previously untreated advanced
non-small cell lung cancer. Lung Cancer. 63:68–71. 2009.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Hiramatsu A, Iwasaki Y, Koyama Y, Tamiya
N, Hosogi S, Nakanishi M, Kohno Y, Ueda M, Arimoto T and Marunaka
Y: Phase II trial of weekly gemcitabine and split-dose cisplatin
for advanced non-small-cell lung cancer. Jpn J Clin Oncol.
39:779–783. 2009.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Berardi R, Porfiri E, Scartozzi M, Lippe
P, Silva RR, Nacciarriti D, Menichetti ET, Tummarello D, Carle F,
Piga A and Cellerino R: Elderly patients with advanced non-small
cell lung cancer: A phase II study with weekly cisplatin and
gemcitabine. Oncology. 65:198–203. 2003.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Horinouchi H, Kubota K, Itani H, Taniyama
TK, Nakamichi S, Wakui H, Kanda S, Nokihara H, Yamamoto N, Sekine I
and Tamura T: Short hydration in chemotherapy containing cisplatin
(≥75 mg/m2) for patients with lung cancer: A prospective study. Jpn
J Clin Oncol. 43:1105–1109. 2013.PubMed/NCBI View Article : Google Scholar
|
